Moteur de recherche d’entreprises européennes
Financement de l’UE (8 200 000 €) : Nouveaux critères d’évaluation cliniques dans le syndrome de Gougerot-Sjögren primitif : un essai interventionnel basé sur la stratification des patients Hor01/01/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Nouveaux critères d’évaluation cliniques dans le syndrome de Gougerot-Sjögren primitif : un essai interventionnel basé sur la stratification des patients
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease (AID) involving 0.5 to 3/1000 persons. The disease affects exocrine glands leading to dryness of the eyes and the mouth and is associated with fatigue and limb pain. In 30% to 50% of the patients, systemic and extra-glandular manifestations may develop. The spectrum of extra-glandular manifestations in pSS is broad and includes vasculitis, peripheral neuropathy, synovitis, kidney involvement and interstitial lung disease. Moreover, pSS patients have a 10 to 20-fold higher risk of developing B cell lymphomas, conferring shorter lifetime expectancy to these patients. Whereas 10 new targeted-immunomodulatory treatments have been marketed for rheumatoid arthritis in the past 20 years, only one drug has been licensed for other systemic AIDs, such as pSS and systemic erythematous lupus in the same period. There are several factors that may hamper the development of successful drugs for AID. Being multi-organ, these AIDs are considerably heterogeneous among individuals both in terms of clinical manifestations and biological disturbances, with, as a consequence, a great difficulty to set-up accurate composite clinical end-points sensitive to change and usable in clinical trials. In this project, our objectives are: • To develop and assess sensitive clinical endpoints, for use in future clinical trials, able to evaluate response to drug treatments in patients with pSS with high disease burden and/or systemic involvement, • To identify and evaluate discriminative biomarkers for stratification of pSS patients predictive of organ involvement and disease progression and thus available for inclusion in clinical trials, • To set-up and perform an original multi-arm multi-stage clinical trial to validate the newly defined pSS endpoints and the identified biomarkers, by maximizing the chance of finding a difference between the placebo arm and the treated arm.
| Academisch Ziekenhuis Groningen | 137 661 € |
| Assistance Publique Hopitaux de Paris | 2 729 817 € |
| Association Francaise Gougerot-Sjogren | 50 000 € |
| 0,00 € | |
| Centre Hospitalier Regional et Universitaire de Brest | 0,00 € |
| Ecrin European Clinical Research Infrastructure Network | 815 009 € |
| 130 319 € | |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 226 675 € |
| 50 000 € | |
| 0,00 € | |
| Helse Stavanger HF | 101 397 € |
| Hopitaux Universitaires de Strasbourg | 337 733 € |
| Hospital Clinic de Barcelona | 0,00 € |
| 300 000 € | |
| Institut National de la Sante et de la Recherche Medicale | 932 235 € |
| Institut Pasteur | 118 733 € |
| Institut de Recherches Internationales Servier Iris | 0,00 € |
| Karolinska Institutet | 251 250 € |
| NOVARTIS PHARMA AG | 0,00 € |
| Queen Mary University of London | 342 941 € |
| The University of Birmingham | 327 402 € |
| UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK | 0,00 € |
| Universita Degli Studi DI Udine | 100 000 € |
| Universitair Medisch Centrum Utrecht | 196 493 € |
| Universite Paris Cite | 224 224 € |
| Universite Paris-Saclay | 0,00 € |
| Universite de Bretagne Occidentale | 427 719 € |
| Universitetet I Bergen | 19 818,98 € |
| University of Newcastle Upon Tyne | 380 573 € |
https://cordis.europa.eu/project/id/806975
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Ziekenhuis Groningen - Financement de l’UE (8 200 000 €) : Nouveaux critères d’évaluation cliniques dans le syndrome de Gougerot-Sjögren primitif : un essai interventionnel basé sur la stratification des patients"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
